Frost & Sullivan honors Epinex Diagnostics, Inc. as the recipient of the 2014 “New Product Innovation Award for Global Diabetes”
September 16, 2015
Epinex Diagnostics has been awarded the New Product Innovation Award (Global Region) in Diabetes Point of Care Diagnostics from the global consulting firm Frost & Sullivan. The award is in recognition of the company’s development of its novel rapid test, the G1A Rapid Diabetes Monitoring Index Test for diabetes management of type 2 and gestational diabetes.
The Epinex G1A test is a patented rapid test that promises to provide patients with a better management tool by directly measuring glycation on a monthly basis, with potential applications in diabetes diagnosis, screening and monitoring. In their analysis, Frost & Sullivan noted that the Epinex test matched a major unmet medical need, and that company was advantageously positioned to potentially change the standard of care for diabetes worldwide. Frost & Sullivan previously recognized Epinex in 2009 with an award for Excellence in Research in the Global Diabetes Market for the company’s work in developing the G1A™ test.
In his congratulatory statement, Frost & Sullivan Senior Vice President Greg Caressi noted, “To achieve leadership in new product innovation is never an easy task, but it is one made even more difficult due to today’s competitive intensity, customer volatility, and economic uncertainty—not to mention the difficulty of innovating in an environment of escalating challenges to intellectual property. Within this context, your receipt of this award signifies an even greater accomplishment.”